GSK’s acquisition of Nuvalent, J&J’s deal for Firefly Bio, and a string of Eli Lilly acquisitions define a …
GSK’s acquisition of Nuvalent, J&J’s deal for Firefly Bio, and a string of Eli Lilly acquisitions define a …
Phase 3 ARTISTRY-1 and ARTISTRY-2 data support an NDA for a single-tablet HIV regimen combining a capsid inhibitor …
A single dose of the lysergide orally disintegrating tablet achieved statistically significant MADRS improvement at six weeks compared …
Amtagvi becomes the first tumour-infiltrating lymphocyte therapy approved in Australia for advanced melanoma, entering a market with the …
Capivasertib plus abiraterone and prednisone clears regulatory hurdle for a molecularly defined patient population with limited prior options, …
BlueRock Therapeutics reports that a single transplant of dopaminergic progenitors derived from pluripotent stem cells produced durable reductions …
The Coinbase CEO-backed longevity company will advance its epigenetic reprogramming mRNA medicine into Phase I trials for fatty …
Tebipenem pivoxil hydrobromide clears regulatory hurdle on resubmission, offering hospitalized patients an oral alternative to intravenous imipenem-cilastatin
The RMAT-designated GABAergic interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy demonstrated sustained seizure control in updated …
The acquisition, announced in March and targeting Centessa’s orexin receptor agonist programme, signals Lilly’s intention to build a …